On July 24th, Gelonhui announced its 2024 interim financial report. During the reporting period, the company's total operating income was 5.65 billion yuan, a year-on-year increase of 11.99%; the net income attributable to shareholders of the listed company was 1.72 billion yuan, a year-on-year increase of 11.61%; and the net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 1.751 billion yuan, a year-on-year increase of 11.03%. Zhangzhou Pientzehuang Pharmaceutical's strong market planning and expanded sales channels were the main reasons for the company's total operating income increasing by 11.99%. Significant growth in sales revenue for the company's core Pientzehuang series products and its wholly-owned subsidiary, Fujian Pientzehuang Cosmetic Co., Ltd. (merged), also contributed to the increase.
The company's total operating income increased by 11.99% year-on-year, mainly due to strengthened market planning and expanded sales channels, resulting in significant growth in sales revenue for the company's core Pientzehuang series products and its controlling subsidiary, Fujian Pientzehuang Cosmetic Co., Ltd. (merged).
